https://betaglue.com

BetaGlue Therapeutics | Targeted Cancer TherapyBetaGlue Therapeutics develops innovative targeted cancer therapy solutions using its proprietary YntraDose technology for nuclear medicine.BetaGlue Therapeutics | Targeted Cancer Therapy Technology Clinical Data Pipeline About Team Events & Media Corporate Governance Contact Open Menu Close Technology Clinical Data Pipeline About Events and Media Team Corporate Governance Contact info@betaglue.com LinkedIn BetaGlue® THERAPEUTICS Targeted nuclear therapies for solid tumours Discover YntraDose Scroll Down A new approach to pancreatic cancer therapyYntraDose brings radiotherapy directly and only to the tumor BetaGlue Therapeutics is pioneering targeted nuclear therapies for solid tumours. By combining biotechnology, nuclear science, and interventional oncology, we are advancing precision radiotherapeutics that deliver radiation directly where it matters most — inside the tumour. YntraDose, our solution, is designed to transform pancreatic cancer treatment through localized, effective, and safe therapy. BetaGlueTherapeutics™ introduces YntraDose® – an innovative Yttrium-90 microsphere radiotherapy solution for the targeted and personalised treatment of solid tumours By offering a novel easy-to-use interventional oncology treatment option YntraDose is set to become the new standard of care for a wide range of solid tumour cancer patient groups where current approaches fall short. Discover YntraDose technology Discover YntraDose technology InnovationTechnology The YntraDose radiotherapy platform is set to enable an entirely new treatment option for the benefit of patients and healthcare professionals alike. Discover our unique technology Discover our unique technology EvidenceClinical Data YntraDose has demonstrated preliminary safety and effectiveness in clinical use. Hear what the clinicians have to say about the potential of our technology. PDACPancreatic cancer demands a different approachHCCHepatocellular CarcinomaDCISDuctal Carcinoma In Situ See all the clinical datas See all the clinical datas LA-PDACWhat comes next in our pipeline YntraDose® is inherently versatile and has the potential to treat a wide range of solid tumour cancer patient groups. See our pipeline steps in details See our pipeline steps in details Pancreas40% Liver78% Breast77% Immuno-Oncology20% ProcessClinical workflow4 steps to unfold YntraDose ® 1 Localize Locate lesion or tumour injection site. 2 Prepare YntraDose-90 added to the YntraDose-Glue syringe. 3 Treat Attached YntraDose-Deliver injection system to YntraDose Syringe. 4 Assess the outcome Assess focalized signal of implantation of YntraDose into injection site. Skip animation LeadershipOur teamMeet BetaGlue’s leadership team, main board and clinical advisory board. Chief Executive Officer (CEO) Alexis Peyroles + 25y Biotech and Pharma experience Chairman Inside Tx & OWL Life Sciences Chief Financial Officer (CFO) Salvatore Calabrese +20 years of experience in the life sciences sector Former CFO at Gain Therapeutics Inc. Head of Manufacturing & Operations Pietro Bubba Bello Former Site Head, Director of Operations, and Plant Director of Operations and HSE Country Manager MD, MSc - Head of Clinical Development Dr. Gianluca De Danieli Former Medical Head, Italy and CEE at Advanced Accelerator Applications Head of RA/QA Gaia Bisaccioni Former Quality Site Head at Advanced Accelerator Applications Head of Product Development Dr. Pieter Janssen 20 years MedTech and Pharmaceutical R&D expertise at Johnson & Johnson, AstraZeneca, Head of Clinical Operations Dr. Carol Hegarty Over 20 years of experience in Clinical Operations within the medical device sector. BetaGlue's Team BetaGlue's Team ProcessWhy we’re here Today, radiotherapy treatment options have varying impact. Stereotactic Body Radiotherapy (SBRT) and Proton Beam Radiotherapy (PBRT), face challenges associated with internal organ movement and patient throughput. They also require substantial investment in specialised equipment and infrastructure, making them less accessible. YntraDose represents a ground-breaking solution by circumventing these limitations. It presents a potential new standard of care that aims to enhance treatment efficacy, reduce side effects, and make personalised cancer treatment more accessible to patients worldwide. About YntraDose © About YntraDose The impact of the clinical benefits for patients thanks to this new personalised radiotherapeutic treatment option are potentially broad. Prof. Jafar Golzarian Clinical advisor, oncology UpdatesLatest from BetaGlueClinical progress and company news from the field BetaGlue Therapeutics Receives Belgium Ministry of Health Approval News 2 min read December 15, 2025 BetaGlue Therapeutics Receives Belgium Ministry of Health Approval BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) Milan, December 15th, 2025 (GlobeNewswire) – BetaGlue® Therapeutics (“BetaGlue” or the…Read more https://betaglue.com/wp-content/uploads/2025/12/BetaGlue-Social-image-Belgium-1.png 1200 800 Betaglue® Therapeutics Betaglue® Therapeutics https://betaglue.com/wp-content/uploads/2025/12/BetaGlue-Social-image-Belgium-1.png December 15, 2025 December 15, 2025 BetaGlue Therapeutics expands Clinical Trial in Italy to conduct its clinical study in unresectable locally advanced pancreatic cancer (uLA-PDAC) News 3 min read December 1, 2025 BetaGlue Therapeutics expands Clinical Trial in Italy to conduct its clinical study in unresectable locally advanced pancreatic cancer (uLA-PDAC) Milan, December 1st, 2025 (GlobeNewsire) BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining approval from the Italian Ministry of Health to conduct clinical study in Unresectable Locally Advanced…Read more https://betaglue.com/wp-content/uploads/2025/12/BetaGlue-PR-image-1.png 1200 800 Betaglue® Therapeutics Betaglue® Therapeutics https://betaglue.com/wp-content/uploads/2025/12/BetaGlue-PR-image-1.png December 1, 2025 December 1, 2025 MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) News Press 2 min read November 12, 2025 MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) Milan, November 12, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, announced today…Read more https://betaglue.com/wp-content/uploads/2025/11/BetaGlue-Social-image-1.png 1200 800 Betaglue® Therapeutics Betaglue® Therapeutics https://betaglue.com/wp-content/uploads/2025/11/BetaGlue-Social-image-1.png November 12, 2025 November 12, 2025 View all Events & Media View all Events & Media Ready to explore YntraDose ? Connect with our team to discuss clinical applications and partnership opportunities Contact Us Contact Us Join our newsletter Don’t miss the updates on our programs and our latest discoveries. Subscribe By subscribing you agree with our Privacy Policy Legal headquarters BetaGlue Therapeutics® BetaGlue Therapeutics SpA Via della Moscova, 3 - 20121 Milan, Italy info@betaglue.com Latest posts BetaGlue Therapeutics Receives Belgium Ministry of Health Approval December 15, 2025 BetaGlue Therapeutics expands Clinical Trial in Italy to conduct its clinical study in unresectable locally advanced pancreatic cancer (uLA-PDAC) December 1, 2025 MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) November 12, 2025 BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer September 22, 2025 MenuTechnology Clinical Data Pipeline About Team Events & Media Corporate Governance Contact YntraDose® is currently under development and is not approved for human use or sale.2025 BetaGlue Therapeutics SpA. All rights reserved | TAX ID number: 06496571214 Privacy Policy Corporate GovernanceCookies Settings All Rights Reserved © - Credits: Projection Web Close Manage Cookies Consent To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions. Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Préférences Préférences L’accès ou le stockage technique est nécessaire dans la finalité d’intérêt légitime de stocker des préférences qui ne sont pas demandées par l’abonné ou l’internaute. Statistics Statistics Le stockage ou l’accès technique qui est utilisé exclusivement à des fins statistiques. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage Cookies consentenusen-US1785475692https://betaglue.com

आफ्नो साइट सम्पादन गर्ने?

के गर्दै हुनुहुन्छ?